In vitro production of cyclic AMP and steroids from an ovarian Sertoli-Leydig cell tumor. Notes on clinical management.
A 27 year old nulliparous woman with a history of chronic anovulation and signs of virilization with a markedly elevated serum level of testosterone, underwent a laparotomy with peroperative bilateral ovarian vein catheterization and bilateral bisection of both ovaries. A solid, 1.5 cm, well delimited tumor located centrally in the right ovary, was excised. Testosterone levels in ovarian venous blood from the tumor bearing side, were 88.4 nmol/l and from the contralateral ovary 3.9 nmol/l. Histopathological examination showed a Sertoli-Leydig cell tumor which was radically extirpated. Postoperatively, the serum levels of androgen normalized, the woman had regular cycles, became pregnant and delivered a normal female baby. Pieces of tumor tissue were incubated for 2 h, with and without addition of gonadotropins and adrenocorticotropic hormone (ACTH). Human chorionic gonadotropin (CG), follicle stimulating hormone (FSH) and adrenocorticotropic hormone (ACTH) caused significant increases in cyclic monophosphate (cAMP) production in tumor tissue in vitro, as compared to controls. Furthermore, ACTH also significantly stimulated 17 beta-estradiol production. In tumor cells cultured for 48 h, FSH slightly, but not significantly, increased the production of progesterone. In the cell culture, [3H]-thymidine incorporation into deoxyribonucleic acid (DNA) was stimulated by IGF1 alpha but not by hCG and FSH. It is concluded that Sertoli-Leydig cell tumors may be sensitive to gonadotropins and ACTH and that their small size, solid shape and intra-ovarian localization can cause diagnostic difficulties.
Abrahamsson
G
G
Department of Obstetrics and Gynecology, University of Göteborg, Sweden.
Dahlgren
E
E
Hahlin
M
M
Knutson
F
F
Norström
A
A
Janson
P O
PO
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D000735:Androstenedione / Q000096:biosynthesis*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D046508:Culture Techniques; D000242:Cyclic AMP / Q000096:biosynthesis*; D004958:Estradiol / Q000096:biosynthesis*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D006801:Humans; D007231:Infant, Newborn; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011184:Postoperative Period; D011247:Pregnancy; D011374:Progesterone / Q000096:biosynthesis*; D018310:Sertoli-Leydig Cell Tumor / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D013739:Testosterone / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured
D006063:Chorionic Gonadotropin; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D000324:Adrenocorticotropic Hormone; D005640:Follicle Stimulating Hormone; D000242:Cyclic AMP